Heidi Splete

ASHEVILLE, N.C. – “Children really do develop contact dermatitis, and they are frequently mislabeled as cases of eczema,” Dr. Bruce Brod said at the annual meeting of the Noah Worcester Dermatological Society.

When taking a history in a child with potential contact dermatitis, keep the most likely allergens in mind, especially nickel, said Dr. Brod of the University of Pennsylvania, Philadelphia. Nickel remains the most common allergen in adults and young children, and more than a quarter of patients are positive on patch testing.

Consider all possible sources of nickel. In addition to the old standbys of jewelry and buckles, ask patients and families about the use of flip-style cell phones, as well as first generation iPads (the cases contained nickel). “Old cell phones do not make great toys,” Dr. Brod emphasized.

Patch testing children with potential contact dermatitis makes sense in several situations, including cases of new-onset dermatitis; progressing or deteriorating dermatitis; involvement of specific body sites, such as the face, eyelids, or neck folds; an increase in the total body surface area affected; clinical presentation of dyshidrosis; and dermatitis that resists standard therapies and only improves with oral or extremely potent topical steroids, he said.

Children with atopic dermatitis are more prone to irritation from patch testing, so shorten the exposure time and use a lower concentration of allergens such as nickel, formaldehyde, and rubber additives, advised Dr. Brod. Shorten the exposure time for children younger than 5 years of age, whether or not they have atopy, he added. Videos or video games can work well as a distraction.

When taking a history, consider the most the common allergens in children, defined in a recent study of patch testing results (Dermatitis 2014;25:345-55), said Dr. Brod. He offered the mnemonic MAFLPP (More Allergies for Lovable Pediatric Patients) to characterize the top categories: metals (nickel and cobalt), antibiotics (neomycin and bacitracin), fragrance (fragrances and balsam of Peru), lanolin, phenylenediamine, and preservatives (including quatemium-15 and methylisothiazolinone).

After patch testing, describe the allergen to patients and their families, and explain where it is found, Dr. Brod said. The site mypatchlink.com has helpful information. Also remind patients to read product labels, and to check pharmacy websites such as drugstore.com or cvs.com.

Members of the American Contact Dermatitis Society can access the Contact Allergen Management Program (CAMP) database to help patients identify allergen-free products based on their patch test results, he said.

Dr. Brod had no relevant financial conflicts to disclose.

hsplete@frontlinemedcom.com

ASHEVILLE, N.C. – “Children really do develop contact dermatitis, and they are frequently mislabeled as cases of eczema,” Dr. Bruce Brod said at the annual meeting of the Noah Worcester Dermatological Society.

When taking a history in a child with potential contact dermatitis, keep the most likely allergens in mind, especially nickel, said Dr. Brod of the University of Pennsylvania, Philadelphia. Nickel remains the most common allergen in adults and young children, and more than a quarter of patients are positive on patch testing.

Consider all possible sources of nickel. In addition to the old standbys of jewelry and buckles, ask patients and families about the use of flip-style cell phones, as well as first generation iPads (the cases contained nickel). “Old cell phones do not make great toys,” Dr. Brod emphasized.

Patch testing children with potential contact dermatitis makes sense in several situations, including cases of new-onset dermatitis; progressing or deteriorating dermatitis; involvement of specific body sites, such as the face, eyelids, or neck folds; an increase in the total body surface area affected; clinical presentation of dyshidrosis; and dermatitis that resists standard therapies and only improves with oral or extremely potent topical steroids, he said.

Children with atopic dermatitis are more prone to irritation from patch testing, so shorten the exposure time and use a lower concentration of allergens such as nickel, formaldehyde, and rubber additives, advised Dr. Brod. Shorten the exposure time for children younger than 5 years of age, whether or not they have atopy, he added. Videos or video games can work well as a distraction.

When taking a history, consider the most the common allergens in children, defined in a recent study of patch testing results (Dermatitis 2014;25:345-55), said Dr. Brod. He offered the mnemonic MAFLPP (More Allergies for Lovable Pediatric Patients) to characterize the top categories: metals (nickel and cobalt), antibiotics (neomycin and bacitracin), fragrance (fragrances and balsam of Peru), lanolin, phenylenediamine, and preservatives (including quatemium-15 and methylisothiazolinone).

After patch testing, describe the allergen to patients and their families, and explain where it is found, Dr. Brod said. The site mypatchlink.com has helpful information. Also remind patients to read product labels, and to check pharmacy websites such as drugstore.com or cvs.com.

Members of the American Contact Dermatitis Society can access the Contact Allergen Management Program (CAMP) database to help patients identify allergen-free products based on their patch test results, he said.

Dr. Brod had no relevant financial conflicts to disclose.

hsplete@frontlinemedcom.com

ASHEVILLE, N.C. – “Children really do develop contact dermatitis, and they are frequently mislabeled as cases of eczema,” Dr. Bruce Brod said at the annual meeting of the Noah Worcester Dermatological Society.

When taking a history in a child with potential contact dermatitis, keep the most likely allergens in mind, especially nickel, said Dr. Brod of the University of Pennsylvania, Philadelphia. Nickel remains the most common allergen in adults and young children, and more than a quarter of patients are positive on patch testing.

Consider all possible sources of nickel. In addition to the old standbys of jewelry and buckles, ask patients and families about the use of flip-style cell phones, as well as first generation iPads (the cases contained nickel). “Old cell phones do not make great toys,” Dr. Brod emphasized.

Patch testing children with potential contact dermatitis makes sense in several situations, including cases of new-onset dermatitis; progressing or deteriorating dermatitis; involvement of specific body sites, such as the face, eyelids, or neck folds; an increase in the total body surface area affected; clinical presentation of dyshidrosis; and dermatitis that resists standard therapies and only improves with oral or extremely potent topical steroids, he said.

Children with atopic dermatitis are more prone to irritation from patch testing, so shorten the exposure time and use a lower concentration of allergens such as nickel, formaldehyde, and rubber additives, advised Dr. Brod. Shorten the exposure time for children younger than 5 years of age, whether or not they have atopy, he added. Videos or video games can work well as a distraction.

When taking a history, consider the most the common allergens in children, defined in a recent study of patch testing results (Dermatitis 2014;25:345-55), said Dr. Brod. He offered the mnemonic MAFLPP (More Allergies for Lovable Pediatric Patients) to characterize the top categories: metals (nickel and cobalt), antibiotics (neomycin and bacitracin), fragrance (fragrances and balsam of Peru), lanolin, phenylenediamine, and preservatives (including quatemium-15 and methylisothiazolinone).

After patch testing, describe the allergen to patients and their families, and explain where it is found, Dr. Brod said. The site mypatchlink.com has helpful information. Also remind patients to read product labels, and to check pharmacy websites such as drugstore.com or cvs.com.

Members of the American Contact Dermatitis Society can access the Contact Allergen Management Program (CAMP) database to help patients identify allergen-free products based on their patch test results, he said.

Dr. Brod had no relevant financial conflicts to disclose.

hsplete@frontlinemedcom.com

ASHEVILLE, N.C. – Building bridges with colleagues in other specialties, especially primary care, helps patients and improves relations among specialties, Dr. Lisa Garner said in an interview at the annual meeting of the Noah Worcester Dermatological Society.

“Communicating is key for patient care,” she said. Dr. Garner, a dermatologist in private practice in Garland, Tex., chaired the American Academy of Dermatology’s Perceptions of Dermatology task force, which assessed perceptions of dermatologists and dermatology within the house of medicine from 2012 to 2014.

Dr. Garner had no financial conflicts to disclose.

ASHEVILLE, N.C. – Building bridges with colleagues in other specialties, especially primary care, helps patients and improves relations among specialties, Dr. Lisa Garner said in an interview at the annual meeting of the Noah Worcester Dermatological Society.

“Communicating is key for patient care,” she said. Dr. Garner, a dermatologist in private practice in Garland, Tex., chaired the American Academy of Dermatology’s Perceptions of Dermatology task force, which assessed perceptions of dermatologists and dermatology within the house of medicine from 2012 to 2014.

Dr. Garner had no financial conflicts to disclose.

ASHEVILLE, N.C. – Building bridges with colleagues in other specialties, especially primary care, helps patients and improves relations among specialties, Dr. Lisa Garner said in an interview at the annual meeting of the Noah Worcester Dermatological Society.

“Communicating is key for patient care,” she said. Dr. Garner, a dermatologist in private practice in Garland, Tex., chaired the American Academy of Dermatology’s Perceptions of Dermatology task force, which assessed perceptions of dermatologists and dermatology within the house of medicine from 2012 to 2014.

Dr. Garner had no financial conflicts to disclose.

ASHEVILLE, N.C. – Building bridges with colleagues in other specialties, especially primary care, helps patients and improves relations among specialties, Dr. Lisa Garner said in an interview at the annual meeting of the Noah Worcester Dermatological Society.

“Communicating is key for patient care,” she said. Dr. Garner, a dermatologist in private practice in Garland, Tex., chaired the American Academy of Dermatology’s Perceptions of Dermatology task force, which assessed perceptions of dermatologists and dermatology within the house of medicine from 2012 to 2014.

Dr. Garner had no financial conflicts to disclose.

hsplete@frontlinemedcom.com

ASHEVILLE, N.C. – Building bridges with colleagues in other specialties, especially primary care, helps patients and improves relations among specialties, Dr. Lisa Garner said in an interview at the annual meeting of the Noah Worcester Dermatological Society.

“Communicating is key for patient care,” she said. Dr. Garner, a dermatologist in private practice in Garland, Tex., chaired the American Academy of Dermatology’s Perceptions of Dermatology task force, which assessed perceptions of dermatologists and dermatology within the house of medicine from 2012 to 2014.

Dr. Garner had no financial conflicts to disclose.

hsplete@frontlinemedcom.com

ASHEVILLE, N.C. – Building bridges with colleagues in other specialties, especially primary care, helps patients and improves relations among specialties, Dr. Lisa Garner said in an interview at the annual meeting of the Noah Worcester Dermatological Society.

“Communicating is key for patient care,” she said. Dr. Garner, a dermatologist in private practice in Garland, Tex., chaired the American Academy of Dermatology’s Perceptions of Dermatology task force, which assessed perceptions of dermatologists and dermatology within the house of medicine from 2012 to 2014.

Dr. Garner had no financial conflicts to disclose.

hsplete@frontlinemedcom.com

ASHEVILLE, N.C. – The incidence of leukocytoclastic vasculitis in the general population is 1.5 to 3 times higher than previously reported, based on data from a large, population-based study.

Based on these findings, leukocytoclastic vasculitis (LCV) is “more common than cutaneous lupus,” said Dr. David A. Wetter of the Mayo Clinic, Rochester, Minn.

Dr. Wetter and his associates reviewed data from all residents of Olmstead County, Minn., with a biopsy-proven diagnosis of LCV from January 1, 1996, through December 31, 2010.

A total of 84 patients were identified, for an overall incidence of 4.5 per 100,000 person-years. The mean age was 48 years, and approximately half were women.

The researchers divided the patients into five subtypes: cutaneous small vessel vasculitis (CSVV), IgA vasculitis, urticarial vasculitis, cryoglobulinemic vasculitis, and antineutrophil cytoplasmic antibody–associated vasculitis.

Systemic involvement occurred in 46% of the patients, with the kidneys involved in 44% of these cases. Recurrent disease was observed in 30% of the 80 patients for whom follow-up data were available.

In addition, LCV was idiopathic in 76% of CSVV patients, significantly higher than the 45% rate reported in the current textbooks, Dr. Wetter noted. Idiopathic LCV also occurred in 96% of patients with IgA vasculitis.

Overall survival was significantly decreased in the LCV patients compared to the general Minnesota population, but the reasons for this difference remain unclear and are worthy of additional study, Dr. Wetter noted. However, survival was not significantly decreased in the subset of patients with IgA vasculitis, despite the high rate of systemic involvement, he added.

Although the study was limited by its retrospective nature and relatively homogeneous white population, it is the first known population-based study of histopathologically-defined LCV, and the data support the evaluation of all patients with LCV “for extracutaneous disease and systemic etiologies for their disease,” Dr. Wetter said.

Dr. Wetter presented the study findings at the annual meeting of the Noah Worcester Dermatological Society. The data also were published in the Mayo Clinic Proceedings in 2014 (Mayo Clin. Proc. 2014;89:1515-24).

Dr. Wetter had no financial conflicts to disclose.

hsplete@frontlinemedcom.com

ASHEVILLE, N.C. – The incidence of leukocytoclastic vasculitis in the general population is 1.5 to 3 times higher than previously reported, based on data from a large, population-based study.

Based on these findings, leukocytoclastic vasculitis (LCV) is “more common than cutaneous lupus,” said Dr. David A. Wetter of the Mayo Clinic, Rochester, Minn.

Dr. Wetter and his associates reviewed data from all residents of Olmstead County, Minn., with a biopsy-proven diagnosis of LCV from January 1, 1996, through December 31, 2010.

A total of 84 patients were identified, for an overall incidence of 4.5 per 100,000 person-years. The mean age was 48 years, and approximately half were women.

The researchers divided the patients into five subtypes: cutaneous small vessel vasculitis (CSVV), IgA vasculitis, urticarial vasculitis, cryoglobulinemic vasculitis, and antineutrophil cytoplasmic antibody–associated vasculitis.

Systemic involvement occurred in 46% of the patients, with the kidneys involved in 44% of these cases. Recurrent disease was observed in 30% of the 80 patients for whom follow-up data were available.

In addition, LCV was idiopathic in 76% of CSVV patients, significantly higher than the 45% rate reported in the current textbooks, Dr. Wetter noted. Idiopathic LCV also occurred in 96% of patients with IgA vasculitis.

Overall survival was significantly decreased in the LCV patients compared to the general Minnesota population, but the reasons for this difference remain unclear and are worthy of additional study, Dr. Wetter noted. However, survival was not significantly decreased in the subset of patients with IgA vasculitis, despite the high rate of systemic involvement, he added.

Although the study was limited by its retrospective nature and relatively homogeneous white population, it is the first known population-based study of histopathologically-defined LCV, and the data support the evaluation of all patients with LCV “for extracutaneous disease and systemic etiologies for their disease,” Dr. Wetter said.

Dr. Wetter presented the study findings at the annual meeting of the Noah Worcester Dermatological Society. The data also were published in the Mayo Clinic Proceedings in 2014 (Mayo Clin. Proc. 2014;89:1515-24).

Dr. Wetter had no financial conflicts to disclose.

hsplete@frontlinemedcom.com

ASHEVILLE, N.C. – The incidence of leukocytoclastic vasculitis in the general population is 1.5 to 3 times higher than previously reported, based on data from a large, population-based study.

Based on these findings, leukocytoclastic vasculitis (LCV) is “more common than cutaneous lupus,” said Dr. David A. Wetter of the Mayo Clinic, Rochester, Minn.

Dr. Wetter and his associates reviewed data from all residents of Olmstead County, Minn., with a biopsy-proven diagnosis of LCV from January 1, 1996, through December 31, 2010.

A total of 84 patients were identified, for an overall incidence of 4.5 per 100,000 person-years. The mean age was 48 years, and approximately half were women.

The researchers divided the patients into five subtypes: cutaneous small vessel vasculitis (CSVV), IgA vasculitis, urticarial vasculitis, cryoglobulinemic vasculitis, and antineutrophil cytoplasmic antibody–associated vasculitis.

Systemic involvement occurred in 46% of the patients, with the kidneys involved in 44% of these cases. Recurrent disease was observed in 30% of the 80 patients for whom follow-up data were available.

In addition, LCV was idiopathic in 76% of CSVV patients, significantly higher than the 45% rate reported in the current textbooks, Dr. Wetter noted. Idiopathic LCV also occurred in 96% of patients with IgA vasculitis.

Overall survival was significantly decreased in the LCV patients compared to the general Minnesota population, but the reasons for this difference remain unclear and are worthy of additional study, Dr. Wetter noted. However, survival was not significantly decreased in the subset of patients with IgA vasculitis, despite the high rate of systemic involvement, he added.

Although the study was limited by its retrospective nature and relatively homogeneous white population, it is the first known population-based study of histopathologically-defined LCV, and the data support the evaluation of all patients with LCV “for extracutaneous disease and systemic etiologies for their disease,” Dr. Wetter said.

Dr. Wetter presented the study findings at the annual meeting of the Noah Worcester Dermatological Society. The data also were published in the Mayo Clinic Proceedings in 2014 (Mayo Clin. Proc. 2014;89:1515-24).

Dr. Wetter had no financial conflicts to disclose.

hsplete@frontlinemedcom.com

Mylan N.V. has announced a voluntary recall of specific lots of injectable products for conditions including rheumatoid arthritis, severe psoriasis, lung cancer, breast cancer, ovarian cancer, and acute nonlymphocytic leukemia because foreign particles were observed during testing of retention samples, according to a statement issued by the company on April 23.

The specific lot numbers can be found on the company’s website.

Affected products include methotrexate injection, USP 25 mg/mL, which is indicated for adult rheumatoid arthritis, severe psoriasis, and some neoplastic diseases. According to Mylan, the contaminated lot was distributed in the United States between Jan. 16, 2014, and March 25, 2014.

Other recalled injectable products include gemcitabine, USP 200 mg, an intravenous product for ovarian cancer, breast cancer, non–small cell lung cancer, and pancreatic cancer; carboplatin 10 mg/mL, indicated for advanced ovarian cancer; and cytarabine, indicated for remission induction in acute nonlymphocytic leukemia in adults and children. The lots for these products were distributed in the United States in various periods of several months during 2014.

The recall is being conducted with the knowledge of the Food and Drug Administration, and any adverse events or quality problems should be reported to the FDA’s MedWatch adverse event reporting program.

hsplete@frontlinemedcom.com

Mylan N.V. has announced a voluntary recall of specific lots of injectable products for conditions including rheumatoid arthritis, severe psoriasis, lung cancer, breast cancer, ovarian cancer, and acute nonlymphocytic leukemia because foreign particles were observed during testing of retention samples, according to a statement issued by the company on April 23.

The specific lot numbers can be found on the company’s website.

Affected products include methotrexate injection, USP 25 mg/mL, which is indicated for adult rheumatoid arthritis, severe psoriasis, and some neoplastic diseases. According to Mylan, the contaminated lot was distributed in the United States between Jan. 16, 2014, and March 25, 2014.

Other recalled injectable products include gemcitabine, USP 200 mg, an intravenous product for ovarian cancer, breast cancer, non–small cell lung cancer, and pancreatic cancer; carboplatin 10 mg/mL, indicated for advanced ovarian cancer; and cytarabine, indicated for remission induction in acute nonlymphocytic leukemia in adults and children. The lots for these products were distributed in the United States in various periods of several months during 2014.

The recall is being conducted with the knowledge of the Food and Drug Administration, and any adverse events or quality problems should be reported to the FDA’s MedWatch adverse event reporting program.

hsplete@frontlinemedcom.com

Mylan N.V. has announced a voluntary recall of specific lots of injectable products for conditions including rheumatoid arthritis, severe psoriasis, lung cancer, breast cancer, ovarian cancer, and acute nonlymphocytic leukemia because foreign particles were observed during testing of retention samples, according to a statement issued by the company on April 23.

The specific lot numbers can be found on the company’s website.

Affected products include methotrexate injection, USP 25 mg/mL, which is indicated for adult rheumatoid arthritis, severe psoriasis, and some neoplastic diseases. According to Mylan, the contaminated lot was distributed in the United States between Jan. 16, 2014, and March 25, 2014.

Other recalled injectable products include gemcitabine, USP 200 mg, an intravenous product for ovarian cancer, breast cancer, non–small cell lung cancer, and pancreatic cancer; carboplatin 10 mg/mL, indicated for advanced ovarian cancer; and cytarabine, indicated for remission induction in acute nonlymphocytic leukemia in adults and children. The lots for these products were distributed in the United States in various periods of several months during 2014.

The recall is being conducted with the knowledge of the Food and Drug Administration, and any adverse events or quality problems should be reported to the FDA’s MedWatch adverse event reporting program.

hsplete@frontlinemedcom.com

SAN FRANCISCO – Formaldehyde has been named the American Contact Dermatitis Society Contact Allergen of the Year for 2015, Dr. David E. Cohen said in the hot topics session at the annual meeting of the American Academy of Dermatology.

Formaldehyde has been a factor in contact dermatitis for a long time, and exposure to it is widespread, said Dr. Cohen of New York University.

However, recent studies have reassessed the clinical relevance of formaldehyde allergy, and a patch test concentration of 2.0% has been recommended by the European Environmental Contact Dermatitis Research group, according to a report published in the journal Dermatitis (Dermatitis 2015;26:3-6).

“Without causing any more irritant reactions, the patch test concentration of 2.0% detects twice as many contact allergies and enables the diagnosis of formaldehyde-allergic patients who otherwise would have been missed,” the authors wrote.

hsplete@frontlinemedcom.com

SAN FRANCISCO – Formaldehyde has been named the American Contact Dermatitis Society Contact Allergen of the Year for 2015, Dr. David E. Cohen said in the hot topics session at the annual meeting of the American Academy of Dermatology.

Formaldehyde has been a factor in contact dermatitis for a long time, and exposure to it is widespread, said Dr. Cohen of New York University.

However, recent studies have reassessed the clinical relevance of formaldehyde allergy, and a patch test concentration of 2.0% has been recommended by the European Environmental Contact Dermatitis Research group, according to a report published in the journal Dermatitis (Dermatitis 2015;26:3-6).

“Without causing any more irritant reactions, the patch test concentration of 2.0% detects twice as many contact allergies and enables the diagnosis of formaldehyde-allergic patients who otherwise would have been missed,” the authors wrote.

hsplete@frontlinemedcom.com

SAN FRANCISCO – Formaldehyde has been named the American Contact Dermatitis Society Contact Allergen of the Year for 2015, Dr. David E. Cohen said in the hot topics session at the annual meeting of the American Academy of Dermatology.

Formaldehyde has been a factor in contact dermatitis for a long time, and exposure to it is widespread, said Dr. Cohen of New York University.

However, recent studies have reassessed the clinical relevance of formaldehyde allergy, and a patch test concentration of 2.0% has been recommended by the European Environmental Contact Dermatitis Research group, according to a report published in the journal Dermatitis (Dermatitis 2015;26:3-6).

“Without causing any more irritant reactions, the patch test concentration of 2.0% detects twice as many contact allergies and enables the diagnosis of formaldehyde-allergic patients who otherwise would have been missed,” the authors wrote.

hsplete@frontlinemedcom.com

Be prepared for more dermal fillers featuring a mix of low- and high-molecular-weight hyaluronic acid, as well as options for customization, said Dr. Nowell Solish.

Such a combination results in a highly crosslinked product that promotes greater duration with less swelling of the product and improved spreadability, he said at the Hawaii Dermatology Seminar sponsored by Global Academy for Medical Education/Skin Disease Education Foundation.

“There is a role for dermal fillers with these characteristics,” said Dr. Solish of the University of Toronto. He compared the uses of several combination products, including Voluma, Volbella, and Volift.

Dr. Solish’s take on Voluma: “Great for volume,” particularly for the chest and midface, with a low and manageable rate of adverse events.

By contrast, Volbella, which is not yet approved for use in the United States, is a fast-flowing filler suited for lip hydration and perioral lines, rather than volume, he said. In a 2012 study, 48% of 58 adult patients showed an improvement of 1 point or higher on the Lip Fullness Scale at 1 year, based on physician assessment, he said (Clin. Cosmet. Investig. Dermatol. 2012;5;167-72).

Volift, another combination high/low-molecular-weight hyaluronic acid product, is “likely last to get approved” in the United States, Dr. Solish said. The product, however, is “great for marionette lines and smile lines,” as well as for improving the appearance of mild to moderate lines around the face.

Emervel is an example of a product in which the varying particle size allows for customization. The hyaluronic acid concentration of Emervel is consistent, but the product is available in three particle sizes for three depths of injection and varying lifting capacity, he explained.

Finally, the use of a filler containing polymethylmethacrylate (PMMA) microspheres was associated with significant improvements in atrophic facial acne scars, Dr. Solish said, citing a recent randomized controlled trial of 147 subjects (J. Am. Acad. Dermatol. 2014;71:77-83). The microspheres are designed to be consistent is size (30-50 mcm). Treatment-related adverse events were generally mild and transient.

The calcium microsphere filler Radiesse with lidocaine was recently approved by the Food and Drug Administration and should be available soon, he added.

Dr. Solish disclosed serving as an investigator and consultant for Allergan, Medicis, Revance Therapeutics, Marz, and Indeed. SDEF and this news organization are owned by the same parent company.

hsplete@frontlinemedcom.com

Be prepared for more dermal fillers featuring a mix of low- and high-molecular-weight hyaluronic acid, as well as options for customization, said Dr. Nowell Solish.

Such a combination results in a highly crosslinked product that promotes greater duration with less swelling of the product and improved spreadability, he said at the Hawaii Dermatology Seminar sponsored by Global Academy for Medical Education/Skin Disease Education Foundation.

“There is a role for dermal fillers with these characteristics,” said Dr. Solish of the University of Toronto. He compared the uses of several combination products, including Voluma, Volbella, and Volift.

Dr. Solish’s take on Voluma: “Great for volume,” particularly for the chest and midface, with a low and manageable rate of adverse events.

By contrast, Volbella, which is not yet approved for use in the United States, is a fast-flowing filler suited for lip hydration and perioral lines, rather than volume, he said. In a 2012 study, 48% of 58 adult patients showed an improvement of 1 point or higher on the Lip Fullness Scale at 1 year, based on physician assessment, he said (Clin. Cosmet. Investig. Dermatol. 2012;5;167-72).

Volift, another combination high/low-molecular-weight hyaluronic acid product, is “likely last to get approved” in the United States, Dr. Solish said. The product, however, is “great for marionette lines and smile lines,” as well as for improving the appearance of mild to moderate lines around the face.

Emervel is an example of a product in which the varying particle size allows for customization. The hyaluronic acid concentration of Emervel is consistent, but the product is available in three particle sizes for three depths of injection and varying lifting capacity, he explained.

Finally, the use of a filler containing polymethylmethacrylate (PMMA) microspheres was associated with significant improvements in atrophic facial acne scars, Dr. Solish said, citing a recent randomized controlled trial of 147 subjects (J. Am. Acad. Dermatol. 2014;71:77-83). The microspheres are designed to be consistent is size (30-50 mcm). Treatment-related adverse events were generally mild and transient.

The calcium microsphere filler Radiesse with lidocaine was recently approved by the Food and Drug Administration and should be available soon, he added.

Dr. Solish disclosed serving as an investigator and consultant for Allergan, Medicis, Revance Therapeutics, Marz, and Indeed. SDEF and this news organization are owned by the same parent company.

hsplete@frontlinemedcom.com

Be prepared for more dermal fillers featuring a mix of low- and high-molecular-weight hyaluronic acid, as well as options for customization, said Dr. Nowell Solish.

Such a combination results in a highly crosslinked product that promotes greater duration with less swelling of the product and improved spreadability, he said at the Hawaii Dermatology Seminar sponsored by Global Academy for Medical Education/Skin Disease Education Foundation.

“There is a role for dermal fillers with these characteristics,” said Dr. Solish of the University of Toronto. He compared the uses of several combination products, including Voluma, Volbella, and Volift.

Dr. Solish’s take on Voluma: “Great for volume,” particularly for the chest and midface, with a low and manageable rate of adverse events.

By contrast, Volbella, which is not yet approved for use in the United States, is a fast-flowing filler suited for lip hydration and perioral lines, rather than volume, he said. In a 2012 study, 48% of 58 adult patients showed an improvement of 1 point or higher on the Lip Fullness Scale at 1 year, based on physician assessment, he said (Clin. Cosmet. Investig. Dermatol. 2012;5;167-72).

Volift, another combination high/low-molecular-weight hyaluronic acid product, is “likely last to get approved” in the United States, Dr. Solish said. The product, however, is “great for marionette lines and smile lines,” as well as for improving the appearance of mild to moderate lines around the face.

Emervel is an example of a product in which the varying particle size allows for customization. The hyaluronic acid concentration of Emervel is consistent, but the product is available in three particle sizes for three depths of injection and varying lifting capacity, he explained.

Finally, the use of a filler containing polymethylmethacrylate (PMMA) microspheres was associated with significant improvements in atrophic facial acne scars, Dr. Solish said, citing a recent randomized controlled trial of 147 subjects (J. Am. Acad. Dermatol. 2014;71:77-83). The microspheres are designed to be consistent is size (30-50 mcm). Treatment-related adverse events were generally mild and transient.

The calcium microsphere filler Radiesse with lidocaine was recently approved by the Food and Drug Administration and should be available soon, he added.

Dr. Solish disclosed serving as an investigator and consultant for Allergan, Medicis, Revance Therapeutics, Marz, and Indeed. SDEF and this news organization are owned by the same parent company.

hsplete@frontlinemedcom.com